EYA1 — Biomarker and therapeutic target for kidney fibrosis The EYA1 splicing was found to be linked with the progression of fibrosis. Patients expressing predominantly EYA1-A ("bad" variant) end up in the end stage renal disease earlier and suffer from a higher mortality. A shift of splicing towards EYA1-C ("good" variant) effectively attenuates fibrosis in vivo (mouse model).
EYA1— Biomarker and Target for kidney fibrosis